comparison of haploidentical bone marrow versus matchet unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Purpose:Posttransplant cyclophosphamide (PTCy) is increas-ingly being utilized as a principle GvHD prophylaxis strategy inallogeneic hematopoietic cell transplantation (allo-HCT). A hap-loidentical (haplo) or matched unrelated donor (UD) is a validoption in the absence of a matched related donor.Experimental Design:We compared the outcomes of patientswith acute leukemia who underwent haplo bone marrow (haplo-BM,N¼401) versus UD mobilized peripheral blood stem cells (UD-PB,N¼192) transplantation in the setting of PTCy.Results:The median follow-up duration was 36 months in thehaplo-BM group and 16.6 months in the UD-PB group, respectively(P<0.01). Myeloablative conditioning was used in 64.6% and 42.7%of haplo-BM and UD-PB patients, respectively (P<0.01). Cumu-lative incidence of neutrophil engraftment at day 30 was 87% inhaplo-BM versus 94% in UD-PB, respectively (P¼0.21). In themultivariate analysis, the risk of grade 2–4 acute GvHD (HR¼0.53,P¼0.01) and chronic GvHD (HR¼0.50,P¼0.02) was signif-icantly lower in the haplo-BM group compared with the UD-PBgroup. There was no significant difference between the studygroups with respect to relapse incidence, nonrelapse mortality,leukemia-fee survival, overall survival, or GvHD-free and relapse-free survival.Conclusions:The use of a haplo donor with a BM graft resultedin a lower incidence of GvHD compared with a UD-PB stem cellgraft in the setting of PTCy for patients with acute leukemia.However, differences in GvHD did not translate into a differencein survival outcomes. Based upon these data, UD-PB or haplo-BMshould be considered equally acceptable sources for allo-HCT
Lingua originaleEnglish
pagine (da-a)843-851
Numero di pagine9
RivistaClinical Cancer Research
Stato di pubblicazionePubblicato - 2021

Keywords

  • comparison of haploidentical bone marrow versus matchet unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia

Fingerprint

Entra nei temi di ricerca di 'comparison of haploidentical bone marrow versus matchet unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia'. Insieme formano una fingerprint unica.

Cita questo